Jin Han

List of Publications by Year
in descending order

54 papers	2,463 citations	361413 20 h-index	197818 49 g-index
55 all docs	55 docs citations	55 times ranked	4075 citing authors

#	Article	IF	Citations
1	The Transcription Factor PLZF Directs the Effector Program of the NKT Cell Lineage. Immunity, 2008, 29, 391-403.	14.3	637
2	The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation. Nature Immunology, 2012, 13, 29-34.	14.5	195
3	Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cellâ€“mediated immune responses. Nature Immunology, 2007, 8, 84-91.	14.5	156
4	Toward Bi³⁺ Red Luminescence with No Visible Reabsorption through Manageable Energy Interaction and Crystal Defect Modulation in Single Bi³⁺-Doped ZnWO₄ Crystal. Chemistry of Materials, 2017, 29, 8412-8424.	6.7	148
5	Redefinition of Crystal Structure and Bi³⁺ Yellow Luminescence with Strong Near-Ultraviolet Excitation in La₃BWO₉:Bi³⁺ Phosphor for White Light-Emitting Diodes. ACS Applied Materials & Interfaces, 2018, 10, 13660-13668.	8.0	144
6	Intrathymic proliferation wave essential for VÎ±14 ⁺ natural killer T cell development depends on c-Myc. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8641-8646.	7.1	100
7	Emission color tuning through manipulating the energy transfer from VO₄^{3â€™} to Eu³⁺ in single-phased LuVO₄:Eu³⁺ phosphors. Journal of Materials Chemistry C, 2017, 5, 390-398.	5.5	83
8	Phenylethyl Isothiocyanate Induces Apoptotic Signaling via Suppressing Phosphatase Activity against c-Jun N-terminal Kinase. Journal of Biological Chemistry, 2002, 277, 39334-39342.	3.4	81
9	Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. Journal of Experimental Medicine, 2009, 206, 707-719.	8.5	81
10	Changing Ce³⁺ Content and Codoping Mn²⁺ Induced Tunable Emission and Energy Transfer in Ca_{2.5}Sr_{0.5}Al₂O₆:Ce³⁺,Mn²⁺. Inorganic Chemistry, 2017, 56, 241-251.	4.0	81
11	HIP-55 Is Important for T-Cell Proliferation, Cytokine Production, and Immune Responses. Molecular and Cellular Biology, 2005, 25, 6869-6878.	2.3	56
12	The SH3 Domain-containing Adaptor HIP-55 Mediates c-Jun N-terminal Kinase Activation in T Cell Receptor Signaling. Journal of Biological Chemistry, 2003, 278, 52195-52202.	3.4	51
13	Actin-Binding Protein 1 Regulates B Cell Receptor-Mediated Antigen Processing and Presentation in Response to B Cell Receptor Activation. Journal of Immunology, 2008, 180, 6685-6695.	0.8	51
14	APOL1 , Î±-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. Haematologica, 2017, 102, e1-e6.	3.5	47
15	Redistribution of Activator Tuning of Photoluminescence by Isovalent and Aliovalent Cation Substitutions in Whitlockite Phosphors. Journal of Physical Chemistry C, 2015, 119, 16853-16859.	3.1	45
16	Identification of CELF splicing activation and repression domains in vivo. Nucleic Acids Research, 2005, 33, 2769-2780.	14.5	41
17	ETR-3 and CELF4 protein domains required for RNA binding and splicing activity in vivo. Nucleic Acids Research, 2004, 32, 1232-1241.	14.5	38
18	Multicolor Emission in a Singleâ€Phase Phosphor Ca₃Al₂O₆:Ce³⁺,Li⁺: Luminescence and Site Occupancy. Journal of the American Ceramic Society, 2014, 97, 1517-1522.	3.8	37

#	Article	IF	Citations
19	Characterization of opioid use in sickle cell disease. Pharmacoepidemiology and Drug Safety, 2018, 27, 479-486.	1.9	37
20	Patterns of opioid use in sickle cell disease. American Journal of Hematology, 2016, 91, 1102-1106.	4.1	24
21	Multisite-Occupancy-Driven Efficient Multiple Energy Transfer: A Straightforward Strategy to Achieve Single-Composition White-Light Emission in Ce³⁺-, Tb³⁺-, and Mn²⁺-Doped Silicate Phosphors. Inorganic Chemistry, 2020, 59, 9838-9846.	4.0	21
22	Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. Human Genetics, 2015, 134, 895-904.	3.8	20
23	HMOX1 and acute kidney injury in sickle cell anemia. Blood, 2018, 132, 1621-1625.	1.4	20
24	Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells following DNA Damage. Molecular Cancer Therapeutics, 2012, 11, 2311-2320.	4.1	16
25	Prediction on Mn⁴⁺â€Doped Germanate Red Phosphor by Crystal Field Calculation on Basis of Exchange Charge Model: A Case Study on K₂Ge₄O₉:Mn⁴⁺. Journal of the American Ceramic Society, 2016, 99, 2388-2394.	3.8	16
26	Risk factors for vitamin D deficiency in sickle cell disease. British Journal of Haematology, 2018, 181, 828-835.	2.5	16
27	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6â€year populationâ€based cohort study. British Journal of Haematology, 2018, 182, 259-270.	2.5	16
28	Outcomes of Rivaroxaban Use in Patients With Sickle Cell Disease. Annals of Pharmacotherapy, 2017, 51, 357-358.	1.9	15
29	Association of Aldosterone Synthase Polymorphism (CYP11B2 -344T>C) and Genetic Ancestry with Atrial Fibrillation and Serum Aldosterone in African Americans with Heart Failure. PLoS ONE, 2013, 8, e71268.	2.5	14
30	Hemolysis and hemolysisâ€related complications in females vs. males with sickle cell disease. American Journal of Hematology, 2018, 93, E376-E380.	4.1	14
31	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a sixâ€year populationâ€based cohort analysis. British Journal of Haematology, 2019, 185, 116-127.	2.5	14
32	Preparation and Luminescence Properties of Eu²⁺ and Mn²⁺ Coactivated Tricalcium Phosphate Phosphors. Journal of the American Ceramic Society, 2014, 97, 3631-3635.	3.8	12
33	Platelets decline during <scp>V</scp>asoâ€occlusive crisis as a predictor of acute chest syndrome in sickle cell disease. American Journal of Hematology, 2015, 90, E228-9.	4.1	12
34	The morbidity and mortality of end stage renal disease in sickle cell disease. American Journal of Hematology, 2019, 94, E138-E141.	4.1	11
35	Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1469-1475.	2.8	10
36	Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. Pharmacotherapy, 2016, 36, 1166-1172.	2.6	10

#	Article	IF	Citations
37	Multispectral tunability in single Eu²⁺-doped (Ba,Sr)₅(PO₄)₃Br phosphor. Inorganic Chemistry Frontiers, 2020, 7, 2515-2522.	6.0	10
38	Erythropoiesisâ€stimulating agents in sickle cell anaemia. British Journal of Haematology, 2018, 182, 602-605.	2.5	9
39	Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis. Journal of Cancer Survivorship, 2020, 14, 294-304.	2.9	9
40	Safety of chronic transdermal fentanyl use in patients receiving hemodialysis. American Journal of Health-System Pharmacy, 2016, 73, 947-948.	1.0	8
41	Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6â€Year Propensity Scoreâ€“Matched Cohort Study. Pharmacotherapy, 2019, 39, 55-66.	2.6	8
42	Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease. Pharmacotherapy, 2015, 35, 696-700.	2.6	7
43	Dual energy transfer controlled photoluminescence evolution in Eu and Mn co-activated Î²-Ca_{2.7}Sr_{0.3}(PO₄)₂phosphors for solid-state lighting. RSC Advances, 2015, 5, 98026-98032.	3.6	7
44	Program expansion of a day hospital dedicated to manage sickle cell pain. American Journal of Hematology, 2018, 93, E20-E21.	4.1	7
45	â€œMaximum tolerated doseâ€•vs â€œfixed lowâ€•doseâ€•hydroxyurea for treatment of adults with sickle cell anemia. American Journal of Hematology, 2019, 94, E112-E115.	4.1	7
46	Use of metformin in patients with sickle cell disease. American Journal of Hematology, 2019, 94, E13-E15.	4.1	5
47	Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. Haematologica, 2017, 102, e282-e284.	3.5	4
48	Kidney ultrasound findings according to kidney function in sickle cell anemia. American Journal of Hematology, 2019, 94, E288-E291.	4.1	4
49	Control of photoluminescence in Ca_{3-3x /7} Y_{2x /7} (PO₄)₂ :Eu²⁺ phosphors by migration of the dopant. Physica Status Solidi - Rapid Research Letters, 2015, 9, 485-488.	2.4	3
50	Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb SÎ²+â€thalassemia sickle cell disease. American Journal of Hematology, 2016, 91, E316-7.	4.1	1
51	Reply to <scp>R</scp>uan <scp>X</scp> et al: â€œA comment on pattern of opioid use in sickle cell diseaseâ€• American Journal of Hematology, 2017, 92, E43.	4.1	1
52	High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. American Journal of Hematology, 2019, 94, E5-E7.	4.1	1
53	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner etÂal. British Journal of Haematology, 2019, 186, 782-783.	2.5	0
54	Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series. Obesity Surgery, 2019, 29, 3762-3764.	2.1	0